Multiple myeloma: most common end-organ damage and management

Area of Science:

• Oncology
• Hematology
• Orthopedics

Background:

• Multiple myeloma (MM) is a plasma cell dyscrasia characterized by end-organ damage.
• Skeletal destruction, particularly vertebral fractures, is a primary cause of morbidity and poor prognosis in MM.
• Early mortality in MM is often linked to active disease, infection, and renal failure.

Purpose of the Study:

• To review recent advances in understanding and managing bone disease in multiple myeloma.
• To discuss the role of bisphosphonates and minimally invasive surgical techniques in skeletal management.
• To highlight strategies for managing infection and renal failure to reduce early mortality.

Main Methods:

• Review of current literature on multiple myeloma bone disease.
• Analysis of bisphosphonate efficacy in preventing skeletal events.
• Evaluation of data on percutaneous vertebroplasty and kyphoplasty for vertebral collapse.
• Discussion of management strategies for infection and renal failure in MM patients.

Main Results:

• Bisphosphonates are crucial in managing skeletal events in MM.
• Minimally invasive techniques like vertebroplasty and kyphoplasty offer effective treatment for vertebral collapse.
• Aggressive management of complications, including infection and renal failure, improves patient morbidity and mortality.
• Targeted therapies and supportive care are enhancing treatment outcomes.

Conclusions:

• Integrated management of bone disease, complications, and the primary MM disease is essential.
• Advances in supportive care and targeted therapies are improving survival and quality of life for MM patients.
• Addressing skeletal complications and early mortality factors is key to realizing the full benefit of new MM therapies.